Bristol-Myers kidney cancer drug meets early success, study stopped

(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial early, despite having reported mixed results on other main goals earlier.